Latest Breaking News On - Transconc type - Page 10 : comparemela.com

Ascendis Pharma A/S (NASDAQ:ASND) Short Interest Update

Ascendis Pharma A/S (NASDAQ:ASND) Short Interest Update
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Ascendis pharmaClearstead advisorsCantor fitzgeraldSkyview investment advisorsMorgan stanleyBelpointe asset managementBessemer group incGet free reportView investment advisorsAsset managementTranscon growth hormoneTranscon parathyroid hormoneTransconc type

Ascendis Pharma A/S (NASDAQ:ASND) Shares Gap Down to $94 94

Ascendis Pharma A/S (NASDAQ:ASND) Shares Gap Down to $94 94
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Ascendis pharmaEvolutionary tree capital managementOsaic holdings incCantor fitzgeraldFinancial services group incMorgan stanleyTekla capital managementTd asset management incGet free reportServices groupTree capital managementCapital managementManagement incTranscon growth hormoneTranscon parathyroid hormoneTransconc type

Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of Moderate Buy from Brokerages

Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of Moderate Buy from Brokerages
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Ascendis pharmaNelson van denburg campbell wealth management groupMorgan stanleyEnvestnet asset management incGuggenheim capitalProfund advisorsChina universal asset management coCantor fitzgeraldGet free reportAsset managementVan denburgCampbell wealth management groupUniversal asset managementGet freeTranscon growth hormoneTranscon parathyroid hormone

Ascendis Pharma A/S (NASDAQ:ASND) Receives Equal Weight Rating from Morgan Stanley

Morgan Stanley restated their equal weight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in a research report report published on Monday morning, Benzinga reports. Morgan Stanley currently has a $109.00 price objective on the biotechnology company’s stock. Several other equities research analysts also recently weighed in on ASND. 3M reaffirmed a […]

New zealand generalNew zealandAscendis pharmaGoldman sachs group incWellington management groupMorgan stanleyAvoro capital advisorsFranklin resources incCantor fitzgeraldT rowe price investment management incFree reportModerate buyManagement groupCapital advisorsRowe price investment managementSachs group

Morgan Stanley Reaffirms Equal Weight Rating for Ascendis Pharma A/S (NASDAQ:ASND)

Morgan Stanley restated their equal weight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in a research report sent to investors on Monday morning, Benzinga reports. They currently have a $109.00 target price on the biotechnology company’s stock. Several other equities research analysts have also recently weighed in on the company. StockNews.com […]

New zealand generalNew zealandAscendis pharmaWellington management groupAscendis pharmaas company profileGoldman sachs group incT rowe price investment management incCantor fitzgeraldAvoro capital advisorsMorgan stanleyFranklin resources incFree reportModerate buyManagement groupCapital advisorsRowe price investment management